Sodium glucose co-transporter 2 (SGLT2) inhibitors are widely used as blood glucose-lowering drugs for the management of type 2 diabetes mellitus (Figure 1) [1,2,3,4,5]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.